ChiCTR2500113247 版本V1.0 版本创建时间2025/11/26 11:36:55 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500113247 

最近更新日期:

Date of Last Refreshed on:

2025-11-26 11:36:15 

注册时间:

Date of Registration:

2025-11-26 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

芳香疗法联合经颅直流电刺激治疗脑卒中后抑郁合并睡眠障碍的随机对照研究

Public title:

Randomized Controlled Trial of Aromatherapy Combined with Transcranial Direct Current Stimulation for Post-Stroke Depression Comorbid with Sleep Disorders

注册题目简写:

English Acronym:

研究课题的正式科学名称:

芳香疗法联合经颅直流电刺激治疗脑卒中后抑郁合并睡眠障碍的应用研究

Scientific title:

Application of Aromatherapy Combined with Transcranial Direct Current Stimulation in the Treatment of Post-Stroke Depression Comorbid with Sleep Disorders

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

崔腾腾 

研究负责人:

崔腾腾 

Applicant:

Tengteng Cui 

Study leader:

Tengteng Cui 

申请注册联系人电话:

Applicant telephone:

+86 198 6140 1810

研究负责人电话:

Study leader's
telephone:

+86 198 6140 1810

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

ctt904427100@163.com

研究负责人电子邮件:

Study leader's E-mail:

ctt904427100@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省潍坊市宝通西街7166号

研究负责人通讯地址:

山东省潍坊市宝通西街7166号

Applicant address:

No. 7166, Baotong West Street, Weifang City, Shandong Province

Study leader's address:

No. 7166, Baotong West Street, Weifang City, Shandong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

山东第二医科大学

Applicant's institution:

Shandong Second Medical University

研究负责人所在单位:

山东第二医科大学

Affiliation of the Leader:

Shandong Second Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025YX211

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

山东第二医科大学医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Shandong Second Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-12 00:00:00

伦理委员会联系人:

王坤

Contact Name of the ethic committee:

Kun Wang

伦理委员会联系地址:

山东第二医科大学浮烟山校区科技楼C座106室

Contact Address of the ethic committee:

Room 106, Building C, Science and Technology Building, Fuyanshan Campus, Shandong Second Medical University

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 536 846 2460

伦理委员会联系人邮箱:

Contact email of the ethic committee:

yxllsc@sdsmu.edu.cn

研究实施负责(组长)单位:

山东第二医科大学

Primary sponsor:

Shandong Second Medical University

研究实施负责(组长)单位地址:

山东省潍坊市宝通西街7166号

Primary sponsor's address:

No. 7166, Baotong West Street, Weifang City, Shandong Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

Shandong

City:

单位(医院):

山东第二医科大学

具体地址:

山东省潍坊市宝通西街7166号

Institution
hospital:

Shandong Second Medical University

Address:

No. 7166, Baotong West Street, Weifang City, Shandong Province

经费或物资来源:

自筹经费

Source(s) of funding:

Self-funded

研究疾病:

脑卒中  

Target disease:

Stroke

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

脑卒中是我国成人死亡和残疾的主要原因,具有高发病率、高复发率、高致残率和高死亡率的特点。卒中后抑郁(PSD)作为脑卒中的继发性疾病之一,表现为持续的情绪低落、兴趣丧失、思维迟钝和精力减退。而卒中后睡眠障碍与PSD之间存在相关性,二者相互作用可形成恶性循环,严重影响康复进程。 项目旨在探究芳香疗法联合经颅直流电刺激治疗PSD合并睡眠障碍的应用效果,具有多方面的临床和现实意义:为脑卒中患者增加非药物、非侵入性治疗的康复选择;进一步加深“嗅觉-神经调控”协同作用机制及临床优势分析;通过评价指标量化分析芳香疗法联合经颅直流电刺激对PSD合并睡眠障碍患者的应用效果,为临床康复提供科学依据。  

Objectives of Study:

Stroke is a leading cause of death and disability among adults in China, characterized by high incidence, recurrence, disability rates, and mortality. Post-stroke depression (PSD), as one of the secondary conditions following stroke, manifests as persistent low mood, loss of interest, slowed thinking, and reduced energy. Post-stroke sleep disorders correlate with PSD, and their interaction can create a vicious cycle that severely impedes rehabilitation progress. This study aims to investigate the therapeutic effects of aromatherapy combined with tDCS on PSD comorbid with sleep disorders, holding significant clinical and practical implications: it expands non-pharmacological and non-invasive rehabilitation options for stroke patients, deepens the analysis of the synergistic mechanisms and clinical advantages of "olfactory-neuromodulation," and quantitatively evaluates the outcomes of this combined intervention through standardized metrics, thereby providing a scientific basis for clinical rehabilitation.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.符合《中国急性缺血性脑卒中诊治指南(2023)》及《中国脑出血诊治指南(2019)》中的诊断标准,并经头颅CT、MRI确诊;2.符合《美国精神障碍诊断与统计手册(第5版)》中因其他躯体疾病而并发抑郁障碍的诊断标准,确诊为PSD,汉密尔顿抑郁量表-17 的评分>7分;匹兹堡睡眠质量指数量表的评分≥7分;3.意识清楚,能正常进行语言沟通;4.情绪障碍出现在脑卒中发生后;5.18周岁<年龄≤80周岁;6.未进行抗抑郁药物治疗;7.自愿参与本研究,已签署知情同意书。

Inclusion criteria

1. Meets the diagnostic criteria outlined in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke (2023) and the Chinese Guidelines for the Diagnosis and Treatment of Cerebral Hemorrhage (2019), and is confirmed by cranial CT or MRI; 2. Meet the diagnostic criteria for depression secondary to other medical conditions in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed as PSD, with Hamilton Depression Rating Scale-17 score >7 points; Pittsburgh Sleep Quality Index score >=7 points; 3. Be conscious and able to communicate verbally normally; 4. Have developed emotional disturbances after the stroke event; 5. Be aged 18 years < age <= 80 years; 6. Have not received antidepressant medication treatment; 7. Voluntarily participate in this study and have signed an informed consent form.

排除标准:

1.病情危重,经医师评定为不宜进行治疗;2.对芳香气味过敏/排斥;3.合并严重的心、肝、肾、肺等脏器功能障碍;4.存在tDCS禁忌症。

Exclusion criteria:

1. Critical condition deemed unsuitable for treatment by medical evaluation; 2. Allergy/aversion to aromatic scents; 3. Severe concomitant dysfunction of vital organs, including heart, liver, kidneys, or lungs; 4. Presence of contraindications for tDCS.

研究实施时间:

Study execute time:

From 2025-12-01 00:00:00 To 2027-12-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-12-20 00:00:00 To 2026-12-20 00:00:00

干预措施:

Interventions:

组别:

观察组

样本量:

43

Group:

Observation Group

Sample size:

干预措施:

经颅直流电刺激

干预措施代码:

Intervention:

Transcranial Direct Current Stimulation

Intervention code:

组别:

对照组

样本量:

43

Group:

Control Group

Sample size:

干预措施:

经颅直流电刺激联合芳香疗法

干预措施代码:

Intervention:

Transcranial Direct Current Stimulation Combined with Aromatherapy

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

Shandong Province

City:

单位(医院):

潍坊市人民医院 

单位级别:

三甲 

Institution
hospital:

Weifang People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

汉密尔顿抑郁量表

指标类型:

主要指标

Outcome:

Hamilton Depression Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

匹兹堡睡眠质量指数量表

指标类型:

主要指标

Outcome:

Pittsburgh Sleep Quality Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁自评量表

指标类型:

次要指标

Outcome:

Self-Rating Depression Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

近红外脑功能成像

指标类型:

次要指标

Outcome:

functional near-infrared spectroscopy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究将采用随机数字表法。首先将86例受试者按入组时间顺序编号(01-86),通过计算机生成随机数字序列,并将随机数字与受试者编号一一对应。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method. The specific grouping method was as follows: First, the 86 subjects were numbered sequentially according to their enrollment time (01-86). A computer-generated random number sequence was then created, and each random number was paired with a subject number.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对受试者和结局评估者实施盲法

Blinding:

Participants and outcome assessors were blinded.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据公众共享时间在试验结束后6个月内,共享平台为ResMan(http://www.medresman.org.cn/)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The raw data will be publicly shared within six months after the completion of the trial.The sharing platform is ResMan (http://www.medresman.org.cn/)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集工作由受过专业培训的科研和临床人员负责,每一个入组的被试均需完成纸质版病例记录表(Case Record Form,CRF)以及相关评估量表,近红外脑功能成像数据由NirLight设备采集,最后将所有的数据进行电子化存档,由专门人员进行数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection is conducted by professionally trained research and clinical personnel. Each enrolled subject must complete a paper-based Case Record Form (CRF) and relevant assessment scales. Near-infrared brain functional imaging data is acquired using the NirLight device. All data is subsequently archived electronically and managed by dedicated personnel.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-11-26 11:36:15